(Ph. Eur. 11.6 update)<\/p>\n
Action and use<\/strong><\/p>\n Inhibition of ATP-dependent potassium channels (sulfonylurea); treatment of diabetes mellitus.<\/p>\n Glimepiride Tablets contain Glimepiride.<\/p>\n The tablets comply with the requirements stated under Tablets and with the following requirements.<\/p>\n Content of glimepiride, C24<\/sub>H34<\/sub>N4<\/sub>O5<\/sub>S<\/strong><\/p>\n 95.0 to 105.0% of the stated amount.<\/p>\n A. Extract a quantity of the powdered tablets containing 10 mg of Glimepiride with 20 mL of acetonitrile, centrifuge and filter the supernatant liquid, evaporate to dryness at a temperature not exceeding 30\u00b0. The infrared absorption spectrum of B. In the Assay, the retention time of the principal peak in the chromatogram obtained with solution (1) is similar to that of the principal peak in the chromatogram obtained with solution (2).<\/p>\n Dissolution<\/strong><\/p>\n Comply with the requirements in the dissolution test for tablets and capsules, Appendix XII B1.<\/p>\n TEST CONDITIONS<\/p>\n (a) Use Apparatus 2, rotating the paddle at 75 revolutions per minute.<\/p>\n (b) Use 900 mL of a pH 7.8 buffer solution prepared by mixing 14.5 g of potassium dihydrogen phosphate and 277.76 g of sodium dihydrogen orthophosphate with sufficient water to make 25 litres, adjusted to pH 7.8 with 10% v\/v orthophosphoric acid or 1M sodium hydroxide, at a temperature of 37\u00b0, as the medium.<\/p>\n PROCEDURE<\/p>\n Carry out the method for liquid chromatography, Appendix III D, using the following solutions. Store the solutions at a temperature not exceeding 12\u00b0 and use within 15 hours.<\/p>\n (1) After 45 minutes withdraw a sample of the medium and filter. Use the filtrate, diluted with the dissolution medium, if necessary, to produce a solution expected to contain 0.0001% w\/v of Glimepiride.<\/p>\n (2) Dilute 1 volume of a 0.001% w\/v solution of glimepiride BPCRS in acetonitrile to 10 volumes with the dissolution medium.<\/p>\n CHROMATOGRAPHIC CONDITIONS<\/p>\n (a) Use a stainless steel column (10 cm \u00d7 4.6 mm) packed with octadecylsilyl silica gel for chromatography (5 \u03bcm) (Phenomenex Lichrospher RP 18 is suitable).<\/p>\n (b) Use isocratic elution and the mobile phase described below.<\/p>\n (c) Use a flow rate of 1 mL per minute.<\/p>\n (d) Use an ambient column temperature.<\/p>\n (e) Use an auto-sampler temperature of 12\u00b0.<\/p>\n (f) Use a detection wavelength of 228 nm.<\/p>\n (g) Inject 50 \u03bcL of each solution.<\/p>\n MOBILE PHASE<\/p>\n Equal volumes of a 0.1% w\/v solution of sodium dihydrogen phosphate dihydrate and acetonitrile R1, the pH adjusted to 2.5 with orthophosphoric acid.<\/p>\n SYSTEM SUITABILITY<\/p>\n The test is not valid unless, in the chromatogram obtained with solution (2), the retention time of glimepiride is about 8 minutes.<\/p>\n DETERMINATION OF CONTENT LIMITS<\/p>\n The amount of glimepiride released is not less than 75% (Q) of the stated amount.<\/p>\n Related substances<\/strong><\/p>\n Carry out the method for liquid chromatography, Appendix III D, using the following solutions in a mixture of 1 volume of water and 4 volumes of acetonitrile. Store the solutions at a temperature not exceeding 12\u00b0 and use within 15 hours.<\/p>\n (1) Shake a quantity of the powdered tablets containing 2 mg of Glimepiride with 8 mL of a mixture of 1 volume of water and 4 volumes of acetonitrile. Dilute to 10 mL with the same solvent, centrifuge and use the supernatant liquid.<\/p>\n (2) Dilute 1 volume of solution (1) to 100 volumes.<\/p>\n (3) 0.04% w\/v of glimepiride for system suitability BPCRS.<\/p>\n (4) Dilute 1 volume of solution (2) to 10 volumes.<\/p>\n CHROMATOGRAPHIC CONDITIONS<\/p>\n (a) Use a stainless steel column (25 cm \u00d7 4 mm) packed with end-capped octadecylsilyl silica gel for chromatography (4 \u03bcm) (Supelco Superspher RP 18 is suitable).<\/p>\n (b) Use isocratic elution and the mobile phase described below.<\/p>\n (c) Use a flow rate of 1 mL per minute.<\/p>\n (d) Use an ambient column temperature.<\/p>\n (e) Use an auto-sampler temperature of 12\u00b0.<\/p>\n (f) Use a detection wavelength of 228 nm.<\/p>\n (g) Inject 10 \u03bcL of each solution.<\/p>\n (h) Allow the chromatography to proceed for 3.5 times the retention time of the peak due to glimepiride.<\/p>\n MOBILE PHASE<\/p>\n Equal volumes of a 0.1% w\/v solution of sodium dihydrogen phosphate dihydrate and acetonitrile R1, the pH adjusted to 2.5 with orthophosphoric acid.<\/p>\n When the chromatograms are recorded under the prescribed conditions, the relative retentions with reference to glimepiride (retention time about 17 minutes) are: impurity B, about 0.24 and impurity C, about 0.3.<\/p>\n SYSTEM SUITABILITY<\/p>\n The test is not valid unless, in the chromatogram obtained with solution (3), the resolution between the peaks due to impurity B and impurity C is at least 4.0.<\/p>\n LIMITS<\/p>\n Identify the peak due to impurity B in solution (1) using solution (3) and multiply the peak area by the correction factor of 0.7.<\/p>\n In the chromatogram obtained with solution (1):<\/p>\n the area of any peak corresponding to impurity B is not greater than twice the area of the principal peak in the chromatogram obtained with solution (2) (2.0%); the sum of the areas of any other secondary peaks is not greater than the area of the principal peak in the chromatogram obtained with solution (2) (1.0%).<\/p>\n Disregard any peak with an area less than the area of the peak due to glimepiride in the chromatogram obtained with solution (4) (0.1%).<\/p>\n Uniformity of content<\/p>\n Tablets containing less than 2 mg and\/or 2% w\/w of Glimepiride comply with the requirements stated under Tablets using the following method of analysis.<\/p>\n Carry out the method for liquid chromatography, Appendix III D, using the following solutions. Store the solutions at a temperature not exceeding 12\u00b0 and use within 15 hours.<\/p>\n (1) To one tablet add 1 mL of water and allow to disintegrate. Add 8 mL of a solution containing 1 volume of water and 9 volumes of acetonitrile, mix with the aid of ultrasound for 15 minutes. Dilute to 10 mL with the same solvent, centrifuge and use the supernatant liquid, diluted if necessary with mobile phase to produce a solution expected to contain 0.01% w\/v of Glimepiride.<\/p>\n (2) 0.01% w\/v of glimepiride BPCRS in a mixture of 1 volume of water and 4 volumes of acetonitrile.<\/p>\n (3) 0.04% w\/v of glimepiride for system suitability BPCRS in a mixture of 1 volume of water and 4 volumes of acetonitrile.<\/p>\n CHROMATOGRAPHIC CONDITIONS<\/p>\n (a) Use a stainless steel column (10 cm \u00d7 4.6 mm) packed with octadecylsilyl silica gel for chromatography (5 \u03bcm) (Phenomenex Lichrospher RP 18 is suitable).<\/p>\n (b) Use isocratic elution and the mobile phase described below.<\/p>\n (c) Use a flow rate of 0.5 mL per minute.<\/p>\n (d) Use an ambient column temperature.<\/p>\n (e) Use an auto-sampler temperature of 12\u00b0.<\/p>\n (f) Use a detection wavelength of 228 nm.<\/p>\n (g) Inject 10 \u03bcL of each solution.<\/p>\n MOBILE PHASE<\/p>\n Equal volumes of a 0.1% w\/v solution of sodium dihydrogen phosphate dihydrate and acetonitrile R1, the pH adjusted to 2.5 with orthophosphoric acid.<\/p>\n SYSTEM SUITABILITY<\/p>\n The test is not valid unless, in the chromatogram obtained with solution (3), the resolution between the peaks due to impurity B and impurity C is at least 4.0.<\/p>\n DETERMINATION OF CONTENT<\/p>\n Calculate the content of C24<\/sub>H34<\/sub>N4<\/sub>O5<\/sub>S in each tablet using the declared content of C24<\/sub>H34<\/sub>N4<\/sub>O5<\/sub>S in glimepiride BPCRS.<\/p>\n For tablets containing less than 2 mg, or 2% w\/w of glimepiride<\/p>\n Use the average of the individual results determined in the test for Uniformity of content.<\/p>\n For tablets containing 2 mg or more, or 2% w\/w or more of glimepiride<\/p>\n Weigh and powder 20 tablets. Carry out the method for liquid chromatography, Appendix III D, using the following solutions<\/p>\n (1) To a quantity of powdered tablets containing 10 mg of Glimepiride, add 80 mL of a solution containing 1 volume of water and 9 volumes of acetonitrile, mix with the aid of ultrasound. Add sufficient of a mixture containing 1 volume of water (2) 0.01% w\/v of glimepiride BPCRS in a mixture of 1 volume of water and 4 volumes of acetonitrile.<\/p>\n (3) 0.04% w\/v of glimepiride for system suitability BPCRS in a mixture of 1 volume of water and 4 volumes of acetonitrile.<\/p>\n CHROMATOGRAPHIC CONDITIONS<\/p>\n The chromatographic conditions described under Uniformity of content may be used.<\/p>\n SYSTEM SUITABILITY<\/p>\n The test is not valid unless, in the chromatogram obtained with solution (3), the resolution between the peaks due to impurity B and impurity C is at least 4.0.<\/p>\n DETERMINATION OF CONTENT<\/p>\n Calculate the content of C24<\/sub>H34<\/sub>N4<\/sub>O5<\/sub>S in the tablets using the declared content of C24<\/sub>H34<\/sub>N4<\/sub>O5<\/sub>S in glimepiride BPCRS.<\/p>\n The impurities limited by the requirements of this monograph include those listed under Glimepiride.<\/p>\n","protected":false},"excerpt":{"rendered":" (Ph. Eur. 11.6 update) Action and use Inhibition of ATP-dependent potassium channels (sulfonylurea); treatment of diabetes mellitus. DEFINITION Glimepiride Tablets contain Glimepiride. The tablets comply with the requirements stated under Tablets and with the following requirements. Content of glimepiride, C24H34N4O5S 95.0 to 105.0% of the stated amount. IDENTIFICATION A. Extract a quantity of the powdered…<\/p>\n","protected":false},"author":4,"featured_media":16096,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[175],"tags":[],"class_list":["post-16094","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-formulated-preparations-specific-monographs"],"acf":[],"_links":{"self":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/16094","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/comments?post=16094"}],"version-history":[{"count":2,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/16094\/revisions"}],"predecessor-version":[{"id":16107,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/16094\/revisions\/16107"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/media\/16096"}],"wp:attachment":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/media?parent=16094"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/categories?post=16094"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/tags?post=16094"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}DEFINITION<\/h2>\n
IDENTIFICATION<\/h2>\n
\nthe residue, Appendix II A, is concordant with the reference spectrum of glimepiride (RS 463).<\/p>\nTESTS<\/h2>\n
\nCalculate the total content of glimepiride, C24<\/sub>H34<\/sub>N4<\/sub>O5<\/sub>S, in the medium from the chromatograms obtained and using the declared content of C24<\/sub>H34<\/sub>N4<\/sub>O5<\/sub>S in glimepiride BPCRS.<\/p>\n
\nthe area of any other secondary peak is not greater than 0.2 times the area of the principal peak in the chromatogram obtained with solution (2) (0.2%);<\/p>\nASSAY<\/h2>\n
\nand 9 volumes of acetonitrile to produce 100 mL, centrifuge and use the supernatant liquid.<\/p>\nIMPURITIES<\/h2>\n